Published in Ann Oncol on November 09, 2011
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA (2014) 6.32
Tumour heterogeneity in the clinic. Nature (2013) 3.92
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol (2015) 2.73
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 2.31
New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol (2013) 2.25
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist (2012) 1.88
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol (2012) 1.71
Molecular biology of lung cancer. J Thorac Dis (2013) 1.67
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature (2014) 1.61
The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol (2012) 1.53
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun (2015) 1.50
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res (2011) 1.50
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res (2015) 1.45
FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol (2012) 1.43
Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res (2013) 1.41
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A (2015) 1.31
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer (2014) 1.30
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res (2015) 1.29
Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther (2013) 1.22
Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res (2012) 1.18
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol (2013) 1.15
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
The evolving genomic classification of lung cancer. J Pathol (2014) 1.08
Program in pharmacogenomics at the Ohio State University Medical Center. Pharmacogenomics (2012) 1.07
Protein signature of lung cancer tissues. PLoS One (2012) 1.06
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem (2012) 1.06
Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol (2014) 1.05
Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol (2013) 1.03
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol (2012) 1.00
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget (2015) 0.97
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev (2014) 0.97
How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health. Health Inf Sci Syst (2013) 0.96
PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. Am J Nucl Med Mol Imaging (2012) 0.96
Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. PLoS One (2015) 0.96
Cancer biomarker discovery and validation. Transl Cancer Res (2015) 0.96
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer (2014) 0.95
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. Oncotarget (2015) 0.94
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel) (2015) 0.93
Genomic oncology education: an urgent need, a new approach. Cancer J (2014) 0.92
Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective. Front Oncol (2014) 0.91
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther (2014) 0.91
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget (2015) 0.90
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. Oncogenesis (2013) 0.89
Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med (2012) 0.89
Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore) (2015) 0.89
Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review. J Exp Clin Cancer Res (2015) 0.89
Emerging therapeutic agents for lung cancer. J Hematol Oncol (2016) 0.88
Farletuzumab in lung cancer. Lung Cancer (2013) 0.88
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget (2014) 0.87
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. Front Oncol (2014) 0.87
Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. Semin Intervent Radiol (2013) 0.86
Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. Breast Cancer Res (2013) 0.85
Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc Natl Acad Sci U S A (2016) 0.84
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay. Chin J Cancer (2014) 0.84
Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. Chin J Cancer (2015) 0.83
Activated RET and ROS: two new driver mutations in lung adenocarcinoma. Transl Lung Cancer Res (2013) 0.81
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther (2013) 0.81
Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther (2014) 0.81
Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Front Oncol (2014) 0.81
Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare adult cases. Am J Clin Pathol (2014) 0.80
Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol (2015) 0.80
The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer. Radiol Oncol (2016) 0.79
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med (2015) 0.79
Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol (2014) 0.78
Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer. Mol Clin Oncol (2013) 0.78
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Front Med (Lausanne) (2017) 0.78
MET Exon 14 Skipping in Non-Small Cell Lung Cancer. Oncologist (2016) 0.77
Afatinib in Non-Small Cell Lung Cancer. J Adv Pract Oncol (2015) 0.75
Targeting SALL4 by entinostat in lung cancer. Oncotarget (2016) 0.75
Profile of farletuzumab and its potential in the treatment of solid tumors. Onco Targets Ther (2016) 0.75
Functionalizing genomic data for personalization of medicine. Clin Pharmacol Ther (2012) 0.75
Non-small cell lung cancer: the era of targeted therapy. Lung Cancer (Auckl) (2012) 0.75
The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Cancer Biol Ther (2015) 0.75
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? J Thorac Dis (2012) 0.75
Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology. Cytojournal (2017) 0.75
Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Res Treat (2016) 0.75
Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. Front Oncol (2014) 0.75
Screening: Smile, they're taking a SNaPshot of your cancer-causing genes. Nat Rev Clin Oncol (2011) 0.75
HeurAA: accurate and fast detection of genetic variations with a novel heuristic amplicon aligner program for next generation sequencing. PLoS One (2013) 0.75
Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. J Int Med Res (2016) 0.75
EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. Target Oncol (2017) 0.75
Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. Cell Biosci (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
New driver mutations in non-small-cell lung cancer. Lancet Oncol (2011) 6.03
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc (2009) 3.61
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol (2010) 2.72
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol (2010) 2.70
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol (2011) 2.58
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res (2009) 2.06
The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat (2003) 1.86
PIK3CA mutation and amplification in human lung cancer. Pathol Int (2007) 1.55
Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol (2008) 1.28
Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene (2001) 1.18
Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol (2004) 1.11
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 8.74
Expression of bacterial genes in plant cells. Proc Natl Acad Sci U S A (1983) 8.70
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem (2001) 7.03
The Arabidopsis abscisic acid response gene ABI5 encodes a basic leucine zipper transcription factor. Plant Cell (2000) 6.18
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
The Arabidopsis abscisic acid response locus ABI4 encodes an APETALA 2 domain protein. Plant Cell (1998) 4.92
Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol (1999) 4.70
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Competition between positive and negative reinforcement in the treatment of escape behavior. J Appl Behav Anal (1999) 3.55
Effects of chiropractic treatment on blood pressure and anxiety: a randomized, controlled trial. J Manipulative Physiol Ther (1988) 3.38
lac repressor can regulate expression from a hybrid SV40 early promoter containing a lac operator in animal cells. Cell (1987) 3.33
Stringent regulation of stably integrated chloramphenicol acetyl transferase genes by E. coli lac repressor in monkey cells. Cell (1988) 3.29
Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med (2001) 3.24
Primary tracheal tumors: treatment and results. Ann Thorac Surg (1990) 3.21
The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J (1998) 3.17
Myosin I is located at the leading edges of locomoting Dictyostelium amoebae. Nature (1989) 3.01
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell (1999) 2.92
Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J Natl Cancer Inst (1999) 2.88
Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J Biol Chem (1997) 2.74
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene (2008) 2.72
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol (2003) 2.63
Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem (2001) 2.62
Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation (1991) 2.62
Postintubation tracheal stenosis. Treatment and results. J Thorac Cardiovasc Surg (1995) 2.61
Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene (1998) 2.56
Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet (1998) 2.56
Retained surgical swabs in 13 dogs. Vet Rec (2011) 2.54
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene (2010) 2.53
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology (1992) 2.27
Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J (1998) 2.23
Regulation and function of the Arabidopsis ABA-insensitive4 gene in seed and abscisic acid response signaling networks. Plant Physiol (2000) 2.21
Gene-target recognition among members of the myc superfamily and implications for oncogenesis. Nat Genet (2000) 2.19
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Physical interactions between ABA response loci of Arabidopsis. Plant J (2001) 2.17
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol (2012) 2.14
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
p63 and p73 in human cancer: defining the network. Oncogene (2007) 2.13
Reinforced primary repair of thoracic esophageal perforation. Ann Thorac Surg (1995) 2.09
Detection and surveillance of colorectal cancer. JAMA (1989) 2.07
The online Cough Clinic: developing guideline-based diagnosis and advice. Eur Respir J (2009) 2.07
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol (2013) 2.06
The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg (2001) 2.05
Stent implantation reduces restenosis in patients with suboptimal results following coronary angioplasty. Eur Heart J (1999) 2.04
Protein activator of cyclic 3':5'-nucleotide phosphodiesterase of bovine or rat brain also activates its adenylate cyclase. Biochem Biophys Res Commun (1975) 2.04
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res (1993) 2.03
Pulmonary arteriovenous malformations: therapeutic options. Ann Thorac Surg (1993) 2.03
Explaining trends in coronary heart disease hospitalisations in New Zealand: trend for admissions and incidence can be in opposite directions. Heart (2008) 2.00
Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol (1999) 1.98
Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis (2000) 1.97
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study. Eur Heart J (1995) 1.97
Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A (2001) 1.97
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol (2007) 1.96
Combined therapy with deferiprone and desferrioxamine. Br J Haematol (1998) 1.91
Management of acquired nonmalignant tracheoesophageal fistula. Ann Thorac Surg (1991) 1.91
p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res (2001) 1.88
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol (2004) 1.85
The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol (1980) 1.81
The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med (1994) 1.80
Bacteriophage T4 regA protein binds to mRNAs and prevents translation initiation. Proc Natl Acad Sci U S A (1987) 1.79
Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. J Biol Chem (1999) 1.79
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol (2005) 1.78
ATPase activities and actin-binding properties of subfragments of Acanthamoeba myosin IA. J Biol Chem (1986) 1.78
Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer (2013) 1.68
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther (2007) 1.67
Infertility and eating disorders. Am J Obstet Gynecol (1990) 1.67
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66
Simian and human immunodeficiency virus Nef proteins use different surfaces to downregulate class I major histocompatibility complex antigen expression. J Virol (2000) 1.66
Association of cigarette smoking and asbestos exposure with location and histology of lung cancer. Am J Respir Crit Care Med (1998) 1.64
Bronchogenic carcinoma with chest wall invasion. Ann Thorac Surg (1991) 1.64
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol (2010) 1.63
Nucleotide sequence of the tmr locus of Agrobacterium tumefaciens pTi T37 T-DNA. Nucleic Acids Res (1984) 1.62
Surgical management and radiological characteristics of bronchogenic cysts. Ann Thorac Surg (1993) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Enterobacteriaceae and Pseudomonas aeruginosa recovered from vegetable salads. Appl Environ Microbiol (1976) 1.60
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res (1999) 1.59
Morphology of ambulatory ST segment changes in patients with varying severity of coronary artery disease. Investigation of the frequency of nocturnal ischaemia and coronary spasm. Br Heart J (1985) 1.58
Mesoderm induction in Xenopus is a zygotic event regulated by maternal VegT via TGFbeta growth factors. Development (1999) 1.57
Home treatment for mental health problems: a systematic review. Health Technol Assess (2001) 1.57
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene (2010) 1.56
Inability of the ST segment/heart rate slope to predict accurately the severity of coronary artery disease. Br Heart J (1984) 1.56
Regulatory factor linked to late-onset diabetes? Nature (1998) 1.55
Ischemia in the ambulatory setting--the total ischemic burden: relation to exercise testing and investigative and therapeutic implications. J Am Coll Cardiol (1989) 1.54
Model-building studies of antigen-binding sites: the hapten-binding site of mopc-315. Cold Spring Harb Symp Quant Biol (1977) 1.54
Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2001) 1.54
Pulmonary artery pressure changes during exercise and daily activities in chronic heart failure. J Am Coll Cardiol (1990) 1.53